Humanin

Quick Facts

Introduction

Humanin is a mitochondrial-derived peptide (MDP) — one of the first such peptides to be discovered — encoded within the mitochondrial genome rather than the nucleus. It was originally identified in research on neuronal survival, where it was noted for its association with protection of cells from a wide range of stress-induced death signals. This cytoprotective character is why Humanin is studied within aging and longevity research, alongside the other principal mitochondrial-derived peptide, MOTS-c.

The conceptual significance of Humanin is that it positioned mitochondria as active signaling organelles, capable of producing peptides that defend the cell and modulate metabolism. Because mitochondrial function and the levels of mitochondrial-derived peptides decline with age, Humanin is studied as a candidate participant in healthspan biology — a theme it shares with longevity-focused compounds such as Epitalon and with mitochondria-targeted peptides like SS-31.

This profile covers what Humanin is, its molecular characteristics as a 24-residue mitochondrial-derived peptide, the anti-apoptotic and receptor-mediated mechanisms it engages, the neuroprotective and metabolic research it appears in, and how it compares with related mitochondrial and longevity compounds. Related entries are catalogued in the peptide database.

What is Humanin?

Humanin is a 24-amino-acid peptide whose coding sequence lies within the mitochondrial 16S ribosomal RNA gene. Like MOTS-c, it is a product of the mitochondrial genome, which distinguishes it from the vast majority of cellular peptides encoded by nuclear DNA and places it in the special category of mitochondrial-derived peptides.

Functionally, Humanin is best known as a cytoprotective and anti-apoptotic signal — a peptide studied for its association with keeping stressed cells alive. It is detectable in circulation and in tissues, and several analogues with enhanced potency (such as the substituted variant often referred to in the literature as a 'potent Humanin analogue') have been generated for research use.

Molecular and structural characteristics

Humanin (sequence MAPRGFSCLLLLTSEIDLPVKRRA) contains a central hydrophobic stretch and a single cysteine residue that contributes to certain forms of self-association. Research has mapped specific residues critical to its activity, and amino-acid substitutions at these positions yield analogues with markedly different potency — a property exploited to create more potent research variants.

As a peptide, Humanin is handled with the standard reconstitution workflow used for the compounds catalogued in the peptide database, in the same manner as its sibling peptide MOTS-c.

Mechanism of action

Humanin is studied as acting through (at least) two complementary mechanisms. The first is intracellular and anti-apoptotic: Humanin is reported to interact with pro-apoptotic members of the Bcl-2 protein family, including Bax and related factors such as BimEL, restraining their ability to permeabilize mitochondria and trigger programmed cell death. By blocking this commitment step, Humanin is associated with keeping stressed cells alive.

The second mechanism is receptor-mediated: extracellular Humanin is reported to signal through a trimeric cell-surface receptor complex (comprising components such as CNTFR, WSX-1, and gp130) and to engage downstream survival pathways including STAT3 signaling. This receptor route is how circulating Humanin is studied as a hormone-like protective signal acting on distant cells.

Together these mechanisms frame Humanin as a stress-resistance factor. Its association with reduced apoptosis and enhanced cellular survival under oxidative and metabolic stress is the through-line connecting its neuroprotective and metabolic research, and it is conceptually adjacent to mitochondria-protective compounds such as SS-31.

• Interaction with pro-apoptotic Bcl-2-family proteins (e.g., Bax, BimEL).
• Inhibition of the mitochondrial apoptosis commitment step.
• Signaling through a trimeric CNTFR/WSX-1/gp130 receptor complex.
• Engagement of STAT3 and other survival pathways.
• Net association with cytoprotection and stress resistance.

Neuroprotection research

Humanin was first identified in research on neuronal survival, where it was noted for its association with protection of neurons against a broad spectrum of insults, including those modeling Alzheimer-type toxicity. In these preclinical models, Humanin and its more potent analogues were associated with reduced neuronal death and preserved function, establishing the peptide's reputation as a cytoprotective factor.

Because this protection appears to operate through fundamental survival machinery rather than a single disease pathway, Humanin is studied across multiple stress models — oxidative injury, ischemia, and excitotoxicity among them. These are mechanistic research observations in models, not demonstrated clinical outcomes, and they situate Humanin within the broader neuroprotection conversation rather than as an established intervention.

Metabolic and aging research

Beyond the nervous system, Humanin is studied for metabolic roles. Research has reported associations between Humanin and improved insulin sensitivity and protection of pancreatic and other cell types under metabolic stress, consistent with its general cytoprotective character. This overlaps in research interest with the metabolic biology of its sibling peptide MOTS-c.

In aging research, circulating Humanin levels have been reported to decline with age in humans and to be comparatively elevated in some long-lived contexts, prompting interest in mitochondrial-derived peptides as biomarkers and modulators of healthspan. This longevity framing connects Humanin to the broader anti-aging research conversation that also includes pineal-axis peptides such as Epitalon — strictly as a research concept, not an established intervention.

Comparison: Humanin vs MOTS-c vs SS-31

Humanin is most usefully compared with MOTS-c, the other principal mitochondrial-derived peptide, and with SS-31, a synthetic mitochondria-targeted peptide. All three concern mitochondrial biology and cellular resilience, but they differ in origin and primary mechanism.

Humanin and MOTS-c are both natural mitochondrial-derived peptides, while SS-31 is a synthetic compound designed to localize to the mitochondrial inner membrane. Full entries for MOTS-c and SS-31 are available, and related compounds are catalogued in the peptide database.

Half-life and pharmacokinetic considerations

As a short native peptide, Humanin is expected to be subject to peptidase degradation, giving an unmodified circulating half-life that is relatively brief — one reason research has generated more stable, potent analogues. Endogenous Humanin is nonetheless detectable in plasma and tissues, indicating it functions as a circulating signal in addition to acting locally.

Because Humanin acts through both intracellular protein interactions and a cell-surface receptor, researchers treat the relationship between circulating levels and downstream effects as context-dependent: the cytoprotective consequences of receptor engagement and apoptosis inhibition can outlast the peptide's presence in circulation. Precise human pharmacokinetic parameters for administered Humanin are not well established.

Reconstitution and handling considerations

Lyophilized Humanin is reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken to protect the peptide. The reconstituted solution should be clear; cloudiness or particulates indicate it should be discarded.

Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear before use.
• Use reconstituted material within a limited window.
• Protect from light and excess warmth.

Storage considerations

Lyophilized Humanin is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting reduces how often a given solution is cycled through freeze–thaw.

Research limitations

Humanin is a research compound whose biology, although foundational to the mitochondrial-derived-peptide field, is still being mapped. Much of the evidence comes from cell and rodent studies, often using potent synthetic analogues rather than the native peptide, and the relative contributions of its intracellular versus receptor-mediated mechanisms remain active research questions. Robust human outcome data are not established. It is described here strictly for research reference.

• Evidence is largely preclinical; human outcome data are limited.
• Many studies use potent analogues rather than native Humanin.
• The balance of intracellular vs receptor-mediated action is still being defined.
• Reported effects are model-, analogue-, and design-dependent.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Hashimoto Y, Niikura T, Tajima H, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proceedings of the National Academy of Sciences USA. 2001.Source
2. Lee C, Yen K, Cohen P. Humanin: a harbinger of mitochondrial-derived peptides? Trends in Endocrinology & Metabolism. 2013.
3. Guo B, Zhai D, Cabezas E, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature. 2003.